API | resatorvid

resatorvid Report issue

Small molecule Experimental

AACT MeSH PubChem

Active Ingredient History

NOW

Resatorvid (TAK-242) is a cyclohexane derivative that was invented by scientists at Takeda in a drug discovery campaign to identify inhibitors of the receptor TLR4. It binds directly to cysteine residue 747 intracellularly, preventing TLR4 binding with TIRAP and thus preventing downstream signal transduction. ^Wikipedia

Chemistry

SMILES: CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl
InChIKey: LEEIJTHMHDMWLJ-CQSZACIVSA-N
Mol. Mass: 361.82
ALogP: 3.26 Partition coefficient
ChEMBL Molecule:
resatorvid

More Chemistry

Pharmacology

Mechanism of Action:
- Toll-like receptor 4 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

cli095 | cli 095 | cli-095 | ethyl 6-(n-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate | ethyl (6r)-6-(n-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate | ethyl cfscc | resatorvid | tak242 | tak 242 | tak-242

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Acute-On-Chronic Liver Failure (Phase 2)

Sepsis (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue